Altimmune Inc
3G0
Company Profile
Business description
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Contact
910 Clopper Road
Suite 201S
GaithersburgMD20878
USAT: +1 240 654-1450
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
57
Stocks News & Analysis
stocks
Tesla: Shares fall as market disappointed with Cybercab launch event
We think Tesla stock is fairly valued.
stocks
The best global tech stocks to buy
These 12 undervalued technology stocks look attractive today.
stocks
Earnings margins to improve for mining specialist
Premium products drive margins yet shares fully valued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,102.90 | 15.70 | -0.17% |
| CAC 40 | 8,156.67 | 161.31 | -1.94% |
| DAX 40 | 25,554.28 | 453.35 | -1.74% |
| Dow JONES (US) | 52,388.09 | 397.98 | -0.75% |
| FTSE 100 | 10,670.06 | 141.60 | -1.31% |
| HKSE | 25,274.96 | 42.22 | -0.17% |
| NASDAQ | 26,242.12 | 179.29 | -0.68% |
| Nikkei 225 | 65,142.78 | 126.55 | -0.19% |
| NZX 50 Index | 13,819.43 | 26.53 | 0.19% |
| S&P 500 | 7,636.83 | 36.69 | -0.48% |
| S&P/ASX 200 | 8,911.40 | 16.20 | -0.18% |
| SSE Composite Index | 3,951.51 | 10.96 | 0.28% |